As of 2025-10-18, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 12.9x | 11.1x |
| Forward P/E multiples | 12.4x - 19.0x | 13.5x |
| Fair Price | (79.11) - (82.95) | (78.56) |
| Upside | -204.1% - -209.1% | -203.4% |
| Date | EV/EBITDA |